Juan Marrone’s Post

The pharmaceutical industry faces complex challenges and significant costs when bringing a new drug to market. Key considerations include: • Research and Development Expenses: These encompass activities such as drug discovery, preclinical studies, and clinical trials and make up a significant portion of the cost of bringing a drug to market. • Regulatory Requirements: The cost of obtaining approval from government agencies like the FDA or EMA adds to the financial burden of drug development. • Production, Marketing, and Post-Market Surveillance: These factors contribute to the overall investment required to bring a drug to market. • Opportunity Costs: The time and resources dedicated to developing one drug can lead to missed opportunities for innovation and addressing unmet medical needs. 🔐 Market access plays a pivotal role in the pharmaceutical industry, with potential impacts including: • Value Optimization: Demonstrating the clinical and economic benefits of treatments to payers, healthcare providers, and patients. • Stakeholder Understanding: Market access professionals work to understand the needs and requirements of different stakeholders within the healthcare ecosystem. • Navigate Market Access Challenges: By understanding health economics, pricing strategies, and reimbursement mechanisms, market access teams can help pharmaceutical companies achieve optimal market access for their products. • Commercial Success: Well-executed market access strategies support the long-term sustainability of pharmaceutical companies' businesses. ***A well-executed market access strategy not only ensures that innovative therapies are adopted by healthcare providers and patients but also supports the long-term sustainability of a pharmaceutical company's business. By effectively navigating market access challenges, pharmaceutical companies can maximize the return on their investment in drug development and ultimately contribute to improving patient outcomes and advancing healthcare innovation. #marketaccess #ai #biopharma

MENA's rapid economic growth and increasing healthcare expenditure make it a key region of opportunity for European pharmaceutical companies looking to grow. However, it's also vastly different to the landscape in Europe, making it challenging for organisations to make the jump alone. Pi Pharma Intelligence can bridge the gap and make the transition smoother, particularly for Spanish companies. We have an expert understanding of the MENA regulatory landscape, helping you to identify the best pathways and streamline your market entry as much as possible. At the same time, we keep an eye on the evolving health needs of the population. This information can prove invaluable for tailoring your R&D efforts to the unique needs of patients in the MENA region. #MENA #Pharmaceuticals #MarketEntry #PharmaRegulation

Sharing my weekly writeup; pharmaceutical companies are increasingly moving beyond traditional roles to engage directly in healthcare implementation, bridging gaps in delivery and improving patient outcomes. The direct link https://lnkd.in/g4JVcDK3

🚀 Breakthrough in Pharmaceutical Market Access Strategies! 🌍 In the rapidly evolving pharmaceutical landscape, market access is more critical than ever for the success of new treatments and innovations. As we navigate complex pricing strategies and regulatory pathways, understanding these dynamics is essential for ensuring that novel therapies reach patients efficiently. 🔍 Key Insights: - Value-Based Pricing: Aligning drug costs with clinical benefits enhances market penetration. - Regulatory Expertise: Navigating approval processes across regions is vital for compliance and expedited access. - Digital Solutions: Leveraging technology and data analytics streamlines market strategies. Collaboration among pharmaceutical companies, regulators, and healthcare providers is key to overcoming challenges in market access. Together, we can drive improvements in global health outcomes! 👉 Click the link to explore more about these transformative strategies! #DigitalHealth #HealthTechnologyAssessment #HealthcareInnovation #MarketAccess #Pharmaceuticals #Publications #ValueBasedPricing #MarketAccess #MarketAccessToday

In the rapidly evolving pharmaceutical industry, one strategy is transforming how companies operate and thrive globally. Regionalization drives innovation, agility, and market success. Want to know more about the key strategies and success stories of industry giants like Novartis, Roche, and AstraZeneca? Click to read more and stay ahead in the competitive landscape! https://lnkd.in/d8y5nY7D #Pharmaceuticals #Innovation #Regionalization #Healthcare #MarketStrategy #PharmaInsights

🌟 Forecasting Sales in the Pharmaceutical Industry 🌟 At Premier Pharmaceutical Consulting, we're dedicated to helping our clients navigate the complexities of forecasting sales for new products and markets. Here are six essential methods we utilize, with examples for a hypothetical new drug launch: 1. **Use Analogies and Scenarios**:   - **Example**: When forecasting sales for a new cholesterol-lowering drug, we might compare it to an existing drug with similar properties and target demographics. We also create scenarios considering factors like changes in healthcare regulations, competition from new drugs, and shifts in patient demand. 2. **Apply Judgmental Methods**:   - **Example**: For our new cholesterol-lowering drug, we gather insights from cardiologists, pharmacists, and patients through surveys and focus groups. This helps us understand potential adoption rates, patient compliance, and market needs. 3. **Build Simulation Models**:   - **Example**: We create a simulation model to predict how the new drug will perform under various pricing strategies, distribution channels, and marketing campaigns. This model considers variables like production costs, potential revenue, and patient behavior. 4. **Combine Multiple Methods**:   - **Example**: To forecast sales for the new drug, we integrate data from analogies, expert opinions, and simulation models. This combined approach provides a more accurate and comprehensive forecast, reflecting different perspectives and reducing potential biases. 5. **Validate and Update Your Forecasts**:   - **Example**: After the new drug is launched, we continuously compare our sales forecasts with actual sales data. We also collect feedback from healthcare professionals and patients, conducting post-launch analyses to refine our forecasts and adjust strategies accordingly. 6. **Seek External Support**:   - **Example**: We collaborate with external Consultancies, Pharmacies, and drug stores who specialize in pharmaceutical sales forecasting, join industry associations for the latest market insights, and subscribe to databases that provide up-to-date information on market trends and competitor activities. By employing these strategies, Premier ensures our clients can confidently forecast sales and make strategic decisions for their new pharmaceutical products and markets. Let's shape the future of healthcare together! 🚀 #PharmaceuticalConsulting #Forecasting #MarketAnalysis #SalesStrategy #HealthcareInnovation #PremierPharmaceuticals

How do we unlock the potential of Africa's pharmaceutical market? Let's get a European perspective 👇 Interesting point of view from Magrietha Mallinson in an article she wrote on European Pharmaceutical Manufacturer on how to tap into one of the few markets that still has a huge ceiling for growth - Africa. It touches on; ✅ Main growth drivers of Africa's pharma sector. ✅ Transforming Africa's healthcare landscape. ✅ Partnering for pharma, with Initiatives like Team Europe on Manufacturing and Access to Vaccines, Medicines and Health Technologies (‘MAV+’). ✅ Tech-enhanced Visibility and Cooperation. ✅ Building a Self-Reliant Africa with the support of Europe’s pharma companies. Find out more: https://lnkd.in/dWrKsewk #afripharmareview #pharmaceuticals #pharmaceuticalindustry

I saw this article with some curiosity and interest. It was posted earlier this week. The author wrote a piece for the journal European Pharmaceutical Manufacturer titled "Unlocking the Potential of Africa's Pharmaceutical Market." I posted a comment putting the author's content into perspective because I believe it was riddled with bias and failed to present a balanced picture of how to unlock the potential of Africa's pharmaceutical market. Clearly, some of my contacts, connections and followers were quick to see my comment, but instead of posting their 'likes' or comments to my comment, they got in touch with me because they thought I had deleted my comment. So I want to put the record straight. NO I DID NOT DELETE MY COMMENT. My working assumption has to be therefore that the author on reading my comment deleted it because it highlighted the bias in the article and thus failed to address the subject matter. I find it amazing quite frankly. There is a saying that "you can fool some of the people some of the time" but in my case, it is "you will rarely fool me at any time" where distributor models and supply chains are the topic and require a subject matter expert. When someone perceives themselves as a "thought leader" they must expect to be challenged on those thoughts by other experts. Note that I avoid the word "other thought leaders" because, to me, I never see myself as a thought leader. Rather thought leadership is bestowed upon an author by the readers. I let readers decide if they see me as a subject matter expert or a thought leader. IF the author deleted my comment, this reveals a true weakness and inability to be challenged. Specifically, my comments were about local manufacturing and why we must stop touting this as the gateway to access issues. It is not. And GSK found out the hard way after sinking monies by moving to a local manufacturing model which was dismantled by a change in CEO several years later. Nobody dismantles a successful model. Or do they? The other point I made was that end-to-end distribution solutions are not a panacea for stockouts and trying to address the inability to deliver the numbers for pharmaceuticals. BUT, such end-to-end services MAY be better positioned to deal with Government procurement relying on bulk purchases and requiring warehousing, logistics and freight management services - for instance with HIV/AIDS drugs, vaccines and donated drugs for neglected tropical diseases where the donation is provided free of charge by the manufacturer but the Government pays the (considerable) fees for the freight management services. Freight management services are not distributors as I define them. They are a form of the verb "to distribute". A distributor is a noun (a thing, a place, a person). Never inter-mingle these terms. Freight management services are 'intermediary partners' offering a service and charge for it. A distributor provides distribution but does not charge for those services.

"Navigating Value-Based Pricing in Pharmaceuticals" by Güvenç Koçkaya has been published! 🚀 Exploring the #transformative approach of #valuebasedpricing in the #pharmaceutical industry offers a promising pathway toward enhancing patient outcomes and ensuring the sustainability of healthcare systems. This #article delves into the complexities and strategic considerations of implementing value-based pricing models, shedding light on how they can lead to more equitable healthcare solutions. A must-read for #healthcare professionals and policymakers committed to innovation and affordability in patient care. Follow the link for the article 👇 https://lnkd.in/dcrisygd #HealthcareInnovation #Pharmaceuticals #ValueBasedPricing #hta #marketaccess #reimbursement #pricing #medicines

"Navigating Value-Based Pricing in Pharmaceuticals" by Güvenç Koçkaya Founder & Partner of ECONiX Research has been published! 🚀 A must-read for #healthcare professionals and policymakers committed to innovation and affordability in patient care. Follow the link for the article 👇 https://lnkd.in/dcrisygd #HealthcareInnovation #Pharmaceuticals #ValueBasedPricing #hta #marketaccess #reimbursement #pricing #medicines